| AQP4 — Aquaporin 4 |
|---|
| Protein Name | Aquaporin 4 |
| Gene | AQP4 |
| UniProt ID | P55064 |
| PDB Structures | 4QK0, 3DL8 |
| Molecular Weight | 34 kDa (monomer) |
| Subcellular Localization | Astrocyte end-feet, perivascular, ependymal |
| Protein Family | Aquaporin (AQP) family |
| Aliases | AQP4, M1-AQP4, M23-AQP4 |
Aquaporin-4 (AQP4) is the principal water channel in the brain, highly expressed in astrocyte end-feet that surround cerebral blood vessels and in ependymal cells lining the ventricles. AQP4 plays a critical role in glymphatic clearance—a brain-wide waste clearance system that removes metabolic byproducts, toxic proteins, and interstitial solutes during sleep. Dysregulation of AQP4 has been implicated in Alzheimer's disease (AD), Parkinson's disease (PD), stroke, traumatic brain injury (TBI), and multiple sclerosis (MS). The protein forms orthogonal arrays of particles (OAPs) in the plasma membrane that mediate rapid water flux between the cerebrospinal fluid (CSF) and interstitial fluid (ISF).
AQP4 exists as two major isoforms:
- M1 isoform (323 aa): Contains the full sequence, localizes to both astrocyte cell bodies and end-feet
- M23 isoform (323 aa): Truncated at the N-terminus, organizes into larger OAPs and is primarily end-foot localized
The protein forms tetramers that assemble into larger orthogonal arrays:
- Monomer: Six transmembrane alpha-helices with cytoplasmic N- and C-termini
- Tetramer: Four monomers form a functional water channel (~4 water molecules per nanosecond)
- OAP (Orthogonal Array of Particles): Multiple tetramers cluster to form large assemblies visible by freeze-fracture electron microscopy
The M23 isoform has a shorter N-terminus that lacks the palmitoylation sites present in M1, allowing more efficient OAP formation.
AQP4 mediates rapid water transport across the blood-brain barrier:
- Glymphatic clearance: CSF flows into the brain along perivascular spaces, then water exits through AQP4 into the interstitium
- Astrocyte volume regulation: AQP4 helps maintain optimal astrocyte hydration
- CSF-ISF exchange: Facilitates bidirectional water flow between fluid compartments
AQP4 works with Kir4.1 potassium channels to buffer extracellular potassium:
- During neuronal activity, potassium is released into the extracellular space
- AQP4-mediated water flux helps disperse potassium
- Coordinated with Kir4.1 for efficient potassium clearance
AQP4 plays complex roles in neuroinflammation:
- Upregulated in reactive astrocytes surrounding lesions
- Involved in edema formation during inflammation
- Regulates immune cell trafficking across the BBB
AQP4 dysfunction significantly impacts AD pathogenesis:
- Impaired amyloid clearance: AQP4 deficiency reduces Aβ clearance by ~40%
- Perivascular AQP4 loss: Reduced AQP4 expression around cerebral vessels in AD patients
- Glymphatic impairment: Sleep-dependent Aβ clearance is AQP4-dependent
- Tau pathology: AQP4 dysfunction may exacerbate tau spread via glymphatic pathways
AQP4 influences PD through multiple mechanisms:
- Alpha-synuclein clearance: Glymphatic system removes extracellular α-syn
- Impaired clearance in PD: Reduced AQP4 expression observed in PD models
- Blood-brain barrier leakage: AQP4 dysregulation contributes to BBB breakdown
- Neuroinflammation: AQP4 affects microglial activation states
¶ Stroke and Traumatic Brain Injury
AQP4 has dual roles in acute brain injury:
- Early phase: Contributes to cytotoxic edema (cell swelling)
- Late phase: Facilitates vasogenic edema resolution
- Therapeutic window: Modulating AQP4 can reduce injury if timed correctly
AQP4 is the autoantigen in neuromyelitis optica (NMO):
- Autoantibodies against AQP4 cause demyelination
- Loss of AQP4 in lesion centers
- Astrocyte dysfunction precedes demyelination
AQP4 represents a therapeutic target for several conditions:
- Glymphatic enhancement: Compounds that increase AQP4 expression or activity could improve waste clearance in AD/PD
- Sleep modulation: Optimizing sleep architecture enhances AQP4-mediated glymphatic clearance
- Anti-AQP4 antibodies: For NMO treatment, approaches to block pathogenic antibodies
- Edema management: AQP4 modulators for stroke and TBI
- Gene therapy: AAV-mediated AQP4 expression for neurodegenerative diseases
AQP4 interacts with:
- Kir4.1 (KCNJ10): Potassium channel coordinate for potassium/water buffering
- Dystroglycan complex: Anchor at astrocyte end-feet
- Mitochondrial proteins: AQP4 localizes to some mitochondrial membranes
- Cytoskeletal proteins: Interaction with actin for membrane anchoring